Related Experiment Videos
US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis
J J Cush1, P Tugwell, M Weinblatt
1University of Texas Southwestern Medical School, Dallas, USA.
Insights
Cyclosporin A (CsA) is an effective second-line treatment for rheumatoid arthritis (RA) patients unresponsive to methotrexate. Careful management of CsA minimizes side effects, offering benefits in severe RA cases.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease causing joint damage and functional loss.
- Managing RA is challenging despite available treatments.
- Cyclosporin A (CsA) has been investigated for RA since 1979.
Purpose of the Study:
- To provide evidence-based recommendations for using CsA in severe RA.
- To guide physicians experienced in systemic immunosuppressive therapy for RA.
Main Methods:
- Review of clinical evidence on CsA use in RA.
- Analysis of trials investigating CsA for RA patients.
- Focus on CsA as a second-line agent and in combination therapy.
Main Results:
- CsA is efficacious as a second-line agent for active RA patients inadequately responding to methotrexate (MTX).
- Combination therapy with CsA and MTX provides clinical benefit for patients with inadequate MTX monotherapy response.
- CsA side effects are manageable with proper dosing, monitoring, and intervention.
Conclusions:
- CsA is a valuable therapeutic option for managing severe RA, particularly in combination with MTX.
- Physicians should adhere to guidelines for safe and effective CsA administration.
- Evidence supports CsA's role in RA treatment when other therapies fail.
Abstract:
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that often leads to irreversible joint damage and loss of function. Although there are numerous treatment options, it is difficult to manage the disease in most patients. Use of cyclosporin A (CsA) for RA was first reported in 1979, and since that time many trials have investigated CsA use for this disease. Based on clinical evidence, CsA is an efficacious second-line agent for patients with active RA who have not responded adequately to methotrexate (MTX). In addition, CsA has been shown to provide clinical benefit when used in combination with MTX in patients responding inadequately to MTX monotherapy. Side effects associated with CsA treatment are manageable if dosing, monitoring, and intervention guidelines are followed. The purpose of this review is to provide recommendations for the use of CsA in severe RA to physicians experienced in the management of systemic immunosuppressive therapy for RA. Where possible and appropriate, recommendations are based on evidence available in the literature.